Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00150
|
|||||
Drug Name |
Acetyl-l-carnitine
|
|||||
Synonyms |
(3S)-3-acetoxy-4-(trimethylammonio)butyrate; 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, hydroxide, inner salt, (R)-; 1-Propanaminium, 2-(acetyloxy)-3-carboxy-N,N,N-trimethyl-, inner salt, (2S)-; 4398-79-2; 521T0J13MA; AC1L2BM0; Acetylcarnitine, (R)-Isomer; Acylcarnitine C2:0; Ammonium, (3-carboxy-2-hydroxypropyl)trimethyl-, hydroxide, inner salt, acetate, L-; C9H18NO4; CAR(2:0); CHEBI:86045; DTXSID90196007; GTPL4520; O-acetyl-D-carnitine; SCHEMBL677128; UNII-521T0J13MA; acetyl-d-carnitine
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Migraine [ICD11: 8A80] | Phase 4 | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C9H17NO4
|
|||||
Canonical SMILES |
CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C
|
|||||
InChI |
InChI=1S/C9H17NO4/c1-7(11)14-8(5-9(12)13)6-10(2,3)4/h8H,5-6H2,1-4H3/t8-/m0/s1
|
|||||
InChIKey |
RDHQFKQIGNGIED-QMMMGPOBSA-N
|
|||||
CAS Number |
CAS 4398-79-2
|
|||||
Pharmaceutical Properties | Molecular Weight | 203.24 | Topological Polar Surface Area | 66.4 | ||
Heavy Atom Count | 14 | Rotatable Bond Count | 5 | |||
Hydrogen Bond Donor Count | 0 | Hydrogen Bond Acceptor Count | 4 | |||
XLogP |
0.4
|
|||||
PubChem CID | ||||||
PubChem SID | ||||||
ChEBI ID |
CHEBI:86045
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | OCTN2 | Transporter Info | Organic cation/carnitine transporter 2 | Substrate | [2] | |
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | OCTN2 | Transporter Info | Km = 8.5 microM | Human embryonic kidney cells (HEK293)-OCTN2 | [2] | |
References | ||||||
1 | ClinicalTrials.gov (NCT01695317) Effect of Acetyl-L-carnitine in Migraine | |||||
2 | Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther. 1999 Nov;291(2):778-84. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.